

## CURRICULUM VITAE

**Name:** Fumiaki Ikeno  
**Date of Birth:** May 4, 1967  
**Place of Birth:** Hamamatsu, Japan  
**Citizenship:** Japan (Permanent Resident of United States of America)  
**Home address:** 691 Terrace Ave  
Half Moon Bay, CA 94019  
**Phone & Fax:** 650-329-9711  
**Business address:** Falk CVRC CV007, 300 Pasteur Dr.  
Stanford, CA 94305-5406  
Phone 650-723-5809  
FAX 650-725-9883  
  
**E-mail address:** [fikeno@stanford.edu](mailto:fikeno@stanford.edu)

**Academic Title at Stanford:**

- Apr/2004- Current    Researcher, **Division of Cardiovascular medicine,**  
Stanford University
- Oct/2018- Current    Director of Japan Outreach,  
**Stanford Center for Asian Health Research and Education**  
<http://med.stanford.edu/care/about/associated-faculty.html>
- Sep 2019-Current    Co-Director of Asia Region, SPARK Global  
Stanford SPARK  
<https://sparkmed.stanford.edu>
- Jan/2015- Current    Program Director (U.S.) Japan Biodesign,  
**Stanford Byers Center for Biodesign, Stanford University**  
<http://biodesign.stanford.edu>
- Jan/2014- Jan/2015    Global Program Development Project Liaison,  
Stanford Biodesign Program
- Sep/2006-June/2007    Graduate Student, Biodesign Certificate Program · Stanford
- Apr/2001- Mar/2004    Post doctoral research fellow,  
Division of Cardiovascular medicine, Stanford University

**Academic Title of other academia:**

- Oct/2015- Current    Consulting Professor, Osaka University, Japan  
**(Japan Biodesign Program in Osaka)**

- Oct/2015- Current      Visiting Lecturer, University of Tokyo, Japan  
**(Japan Biodesign Program in Tokyo)**
- Apr/2018- Current      Visiting Professor, Tohoku University, Japan  
**(Japan Biodesin Program in Tohoku)**
- Apr/2016- Current      Visiting Professor, Tsukuba University, Japan  
**(SPARK Japan in Tsukuba)**  
**(Japan Biodesin Program in Tsukuba)**
- Mar/2016- Current      Visiting Professor, Hiroshima University, Japan  
**(Japan Biodesin Program in Hiroshima)**
- Apr/2019-              Visiting Professor, Tokushima University, Japan  
**(Japan Biodesin Program in Tokushima)**

**Degree and Trainings:**

- Apr/1997-Mar/2001      Medical Staff in Department of Internal medicine, Sakuma  
Hospital, Shizuoka, Japan  
Shizuoka prefectural government, department of health & welfare  
Consulting doctor of Interventional Cardiology, Yaizu Municipal  
Hospital, Yaizu, Japan
- Apr/1994-Mar/1997      Clinical Fellow in Department of Cardiology, Yaizu Municipal  
Hospital, Yaizu, Japan  
Shizuoka prefectural government, department of health & welfare

May/1992-Mar/1994 Resident in Shizuoka Prefecture General Hospital, Shizuoka, Japan  
Shizuoka prefectural government, department of health & welfare

May/1992 Passed the Examination of National Board

1986-1992 M.D. Jichi Medical School, Tochigi, Japan

1986 Graduated from Hamamatsu Kita High School (Hamamatsu)

### **Laboratory Animal Experiences:**

2001～ Stanford University Preclinical Laboratory of cardiovascular medicine  
(Mainly, doing transcatheter study)

Pig: more than 2000 experiences

Rabbit: more than 200

Sheep: 100

Dog: 100

### **GLP (Good Laboratory Practice) Study:**

2012 CV Ingenuity (Palo Alto, CA)

2005 Endotex (Cupertino, CA)

2004 OCT (LightLab, Inc, MA)

2004 NSE Balloon (Goodman, Nagoya)

2003 Cypher Stent (Johnson & Johnson)

2002 AST Bifurcation Stent

2001 Guidant Bifurcation stent

**Core Laboratory Experiences:**

- BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Study (Co-P.I of Angiographic Core Laboratory)
- BARI 2D Ancillary SYNTAX Analysis Study (**Principal Investigator**)
- FAME (Fractional flow reserve vs. Angiography in Multivessel Evaluation) Study
- FUTURE (The First Use To Underscore restenosis Reduction with Everolimus)-I Study

**Data Safety Monitoring Board:**

2008～ ReOpen-I Trial (ReVascular Therapeutics, Inc, Sunnyvale, CA)

**Specialty Certification:**

2001 Japan amateur sports association official sports doctor  
1998 Japan Medical Association Board of Occupational medicine  
1997 Diplomate, Japanese Board of Internal Medicine

**Membership:**

Japanese Society of Internal Medicine  
Japanese Circulation Society  
Japanese College of Cardiology  
Japanese Society of Interventional Cardiology  
Japanese Society of Echocardiography  
Japan Association for Development of Community Medicine  
Faculty member, Complex Catheter Therapeutics

**Patent:**

2010,10 DEVICE TO BE PLACED IN BLOOD VESSEL, ANGIOSTENOSIS  
MODEL USING SAME AND METHOD FOR CONSTRUCTION THEREOF:

WO/2010/100960

2005, 5 METHODS AND COMPOSITION FOR REDUCING ISCHEMIA-DRIVEN  
MICROVASCULAR DAMAGE: PCT/US2005/016114

**Organize committee:**

2020~ American College of Cardiology, Value Based Health Care Initiative Work Group

2013~ Biodesign Japan project supported by Stanford Biodesign founding committee

2012~ PARC (Peripheral Artery Disease Research Consortium) Member

2011~ Japan-US Critical Limb Ischemia Consensus Document Organizing committee

2008~ Harmonization by Doing: Working Group 1 Member

2008~ The International Working Group for Intracoronary OCT Standardization And  
Validation: Member

## Journal Article:

1. Global medical device clinical trials involving both the United States and Japan: Key considerations for development, regulatory approval, and conduct. Iwamoto S, Cavanaugh K, Malone M, Lottes A, Thatcher R, Kumar K, Rowland S, Fearnot N, Uchida T, Iwaishi C, Senshu K, Konishi R, Ikeda K, Suzuki Y, **Ikeno F**, Tamura A, Ho M, Ohashi M, Katayama H, Krucoff MW. *Cardiovasc Revasc Med*. 2023 Feb 24:S1553-8389(23)00071-4. doi: 10.1016/j.carrev.2023.02.015. Online ahead of print. PMID: 36870799
2. The associations of the national health and productivity management program with corporate profits in Japan. Yano Y, Kanegae H, Node K, Mizuno A, Nishiyama A, Rakugi H, Itoh H, Kitaoka K, Kashihara N, **Ikeno F**, Tsuji I, Okada K. *Epidemiol Health*. 2022;44:e2022080. doi: 10.4178/epih.e2022080. Epub 2022 Sep 23.
3. Japan-USA Orbital Atherectomy for Calcific Coronary Lesions: COAST Study, Harmonization by Doing Proof-of-Concept. Martinsen BJ, Kumar K, Saito S, Sharma SK,

**Ikeno F**, Fearnot NE, Shlofmitz RA, Thatcher R, Krucoff MW. *Cardiovasc Revasc Med*.

2022 Apr;37:112-117. doi: 10.1016/j.carrev.2021.08.021. Epub 2021 Aug 26. PMID:

34607786

4. In Vivo Translation of the CIRPI System---Revealing Molecular Pathology of Rabbit Aortic Atherosclerotic Plaques. Zaman R, Yousufi S, Chibana H, **Ikeno F**, Long SR, Gambhir SS, Chin FT, McConnell MV, Xing L, Yeung A. *J Nucl Med*. 2019 Feb 8. pii: jnumed.118.222471. doi: 10.2967/jnumed.118.222471.
  
5. Usability of cardiac magnetic resonance imaging for procedural myocardial infarction undergoing rotational atherectomy. Chibana H, **Ikeno F**. *J Thorac Dis*. 2018 Sep;10(Suppl 26):S3237-S3240. doi: 10.21037/jtd.2018.08.90. No abstract available.
  
6. The East-West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts. Harrison RW, Radhakrishnan V,



Allen JC Jr, Lam PS, Allocco DJ, Brar S, Fahy M, Zhang Z, Fisher R, **Ikeno F**, G n reux P, Kimura T, Liu M, Lye WK, Nagai H, Suzuki Y, White R, Krucoff MW. Am Heart J. 2018 Dec;206:61-71. doi: 10.1016/j.ahj.2018.08.017. Epub 2018 Sep 7.

7. Design Strategies for Global Clinical Trials of Endovascular Devices for Critical Limb

Ischemia (CLI) - A Joint USA-Japanese Perspective. Yokoi H, Ho M, Iwamoto S, Suzuki Y, Ansel GM, Azuma N, Handa N, Iida O, Ikeda K, **Ikeno F**, Ohura N, Rosenfield K, Rundback J, Terashi H, Uchida T, Yokoi Y, Nakamura M, Jaff MR. Circ J. 2018 Aug;82(9):2233-2239. doi: 10.1253/circj.CJ-18-0014. Epub 2018 Jun 30.

8. Dose-Dependent Cardioprotection of Moderate (32 C) Versus Mild (35 C) Therapeutic

Hypothermia in Porcine Acute Myocardial Infarction. Dash R, Mitsutake Y, Pyun WB, Dawoud F, Lyons J, Tachibana A, Yahagi K, Matsuura Y, Kolodgie FD, Virmani R, McConnell MV, Illindala U, **Ikeno F**, Yeung A. JACC Cardiovasc Interv. 2018 Jan 22;11(2):195-205. doi: 10.1016/j.jcin.2017.08.056.

9. Correction to: Cost-effectiveness of orbital atherectomy compared to rotational atherectomy in treating patients with severely calcified coronary artery lesions in Japan. Pietzsch JB, Geisler BP, Ikeno F. *Cardiovasc Interv Ther*. 2018 Oct;33(4):337. doi: 10.1007/s12928-017-0492-7.
10. Cost-effectiveness of orbital atherectomy compared to rotational atherectomy in treating patients with severely calcified coronary artery lesions in Japan. Pietzsch JB, Geisler BP, Ikeno F. *Cardiovasc Interv Ther*. 2017 Sep 5. doi: 10.1007/s12928-017-0488-3. [Epub ahead of print]
11. Differences in Vascular Response between Balloon Overstretch and Stent Overexpansion in Nonatherosclerotic Porcine Coronary Arteries. Mitsutake Y, Reifart J, Pyun WB, Lyons JK, Deuse T, Schrepfer S, Ikeno F. *Comp Med*. 2017 Aug 1;67(4):350-355.

12. Improvement of local cell delivery using Helix transendocardial delivery catheter in healthy porcine heart. Yoshiaki Mitsutake, Wook Bum Pyun, Didier Rouy, Cheryl Wong Po Foo, Simon H. Stertzler, Peter Altman, **Fumiaki Ikeno**. *International Heart Journal* (*in press*)
  
13. SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial. **Ikeno F**, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group. *J Am Coll Cardiol*. 2017 Jan 31;69(4):395-403.
  
14. [Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis](#). Rimal G, Fearon WF, De Bruyne B, **Ikeno F**, Matsuo H, Piroth Z, Costerousse O, Bertrand OF. *Am Heart J*. 2017 Jan;183:1-9.
  
15. [Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts](#). Harrison RW,

Radhakrishnan V, Lam PS, Allocco DJ, Brar S, Fahy M, Fisher R, **Ikeno F**, Génereux P,

Kimura T, Liu M, Lye WK, Mintz GS, Nagai H, Suzuki Y, White R, Allen JC Jr, Krucoff

MW. *Am Heart J*. 2016 Dec;182:103-110.

16. [Multimodality Molecular Imaging of Cardiac Cell Transplantation: Part II. In Vivo Imaging](#)

[of Bone Marrow Stromal Cells in Swine with PET/CT and MR Imaging.](#) Parashurama N,

Ahn BC, Ziv K, Ito K, Paulmurugan R, Willmann JK, Chung J, **Ikeno F**, Swanson JC,

Merk DR, Lyons JK, Yerushalmi D, Teramoto T, Kosuge H, Dao CN, Ray P, Patel M,

Chang YF, Mahmoudi M, Cohen JE, Goldstone AB, Habte F, Bhaumik S, Yaghoubi S,

Robbins RC, Dash R, Yang PC, Brinton TJ, Yock PG, McConnell MV, Gambhir SS.

*Radiology*. 2016 Jun 22:151150.

17. [Multimodality Molecular Imaging of Cardiac Cell Transplantation: Part I. Reporter Gene](#)

[Design, Characterization, and Optical in Vivo Imaging of Bone Marrow Stromal Cells after](#)

[Myocardial Infarction.](#) Parashurama N, Ahn BC, Ziv K, Ito K, Paulmurugan R, Willmann

JK, Chung J, **Ikeno F**, Swanson JC, Merk DR, Lyons JK, Yerushalmi D, Teramoto T, Kosuge H, Dao CN, Ray P, Patel M, Chang YF, Mahmoudi M, Cohen JE, Goldstone AB, Habte F, Bhaumik S, Yaghoubi S, Robbins RC, Dash R, Yang PC, Brinton TJ, Yock PG, McConnell MV, Gambhir SS. *Radiology*. 2016 Jun 16:140049.

18. [Acute stent recoil and optimal balloon inflation strategy: an experimental study using real-time optical coherence tomography.](#) Kitahara H, Waseda K, Yamada R, Otagiri K, Tanaka S, Kobayashi Y, Okada K, Kume T, Nakagawa K, Teramoto T, **Ikeno F**, Yock PG, Fitzgerald PJ, Honda Y. *EuroIntervention*. 2016 Jun 12;12(2):e190-8.

19. [Quantitative precision of optical frequency domain imaging: direct comparison with frequency domain optical coherence tomography and intravascular ultrasound.](#) Kobayashi Y, Kitahara H, Tanaka S, Okada K, Kimura T, **Ikeno F**, Yock PG, Fitzgerald PJ, Honda Y. *Cardiovasc Interv Ther*. 2015 Aug 14

20. [Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human Experience.](#) Fischell TA, Ebner A, Gallo S, **Ikeno F**, Minarsch L, Vega F, Haratani N, Ghazarossian VE. *JACC Cardiovasc Interv.* 2016 Mar 28;9(6):589-98.
21. Quantitative precision of optical frequency domain imaging: direct comparison with frequency domain optical coherence tomography and intravascular ultrasound. Kobayashi Y, Kitahara H, Tanaka S, Okada K, Kimura T, **Ikeno F**, Yock PG, Fitzgerald PJ, Honda Y. *Cardiovasc Interv Ther.* 2016 Apr;31(2):79-88. doi: 10.1007/s12928-015-0349-x. Epub 2015 Aug 14.
22. [Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.](#) Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group. *N Engl J Med.* 2015 Aug 13;373(7):610-20.

23. [Manganese-Enhanced Magnetic Resonance Imaging Enables In Vivo Confirmation of Peri-Infarct Restoration Following Stem Cell Therapy in a Porcine Ischemia-Reperfusion Model.](#) Dash R, Kim PJ, Matsuura Y, **Ikeno F**, Metzler S, Huang NF, Lyons JK, Nguyen PK, Ge X, Foo CW, McConnell MV, Wu JC, Yeung AC, Harnish P, Yang PC. *J Am Heart Assoc.* 2015 Jul 27;4(7).
24. [Optical Coherence Tomography of Pulmonary Arterial Walls in Humans and Pigs \(\*Sus scrofa domestica\*\).](#) Brunner NW, Zamanian RT, **Ikeno F**, Mitsutake Y, Connolly AJ, Shuffle E, Yuan K, Orcholski M, Lyons J, de Jesus Perez VA. *Comp Med.* 2015 Jun;65(3):217-24.
25. [Serial changes of coronary endothelial function and arterial healing after paclitaxel-eluting stent implantation.](#) Mitsutake Y, Ueno T, **Ikeno F**, Yokoyama S, Sasaki K, Nakayoshi T, Itaya N, Chibana H, Sasaki M, Fukumoto Y. *Cardiovasc Interv Ther.* 2016 Jan;31(1):21-8.

26. [Evaluation and treatment of patients with lower extremity peripheral artery disease:](#)

[consensus definitions from Peripheral Academic Research Consortium \(PARC\).](#) Patel MR,

Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, **Ikeno F**,

Jaff MR, Jones WS, Kawahara M, Lookstein RA, Mehran R, Misra S, Norgren L, Olin JW,

Povsic TJ, Rosenfield K, Rundback J, Shamoun F, Tcheng J, Tsai TT, Suzuki Y, Vranckx P,

Wiechmann BN, White CJ, Yokoi H, Krucoff MW.

*J Am Coll Cardiol.* 2015 Mar 10;65(9):931-41.

27. [Echocardiographic and electrocardiographic characteristics of male and female squirrel](#)

[monkeys \(Saimiri spp.\).](#) Huss MK, **Ikeno F**, Buckmaster CL, Albertelli MA.

*J Am Assoc Lab Anim Sci.* 2015 Jan;54(1):25-8.

28. [Efficacy and safety of novel multi-lumen catheter for chronic total occlusions: from](#)

[preclinical study to first-in-man experience.](#) Mitsutake Y, Ebner A, Yeung AC, Taber MD,



Davidson CJ, **Ikeno F**. *Catheter Cardiovasc Interv*. 2015 Feb 15;85(3):E70-5.

29. [Dichloroacetate prevents restenosis in preclinical animal models of vessel injury](#). Deuse T, Hua X, Wang D, Maegdefessel L, Heeren J, Scheja L, Bolaños JP, Rakovic A, Spin JM, Stubbendorff M, **Ikeno F**, Länger F, Zeller T, Schulte-Uentrop L, Stoehr A, Itagaki R, Haddad F, Eschenhagen T, Blankenberg S, Kiefmann R, Reichenspurner H, Velden J, Klein C, Yeung A, Robbins RC, Tsao PS, Schrepfer S.

*Nature*. 2014 May 29;509(7502):641-4.

30. [Histological characteristics of myocardial bridge with an ultrasonic echolucent band. Comparison between intravascular ultrasound and histology](#). Yamada R, Turcott RG, Connolly AJ, **Ikeno F**, McConnell MV, Schnittger I, Fitzgerald PJ, Honda Y.
- Circ J*. 2014;78(2):502-4.

31. [The role of large animal studies in cardiac regenerative therapy concise review of translational stem cell research](#). Kwon SU, Yeung AC, **Ikeno F**. *Korean Circ J*. 2013 Aug;43(8):511-8.

32. [Patient access to medical devices-what about Japan, the second largest medical device](#)

[market?](#) **Ikeno F**, Ikeda K, Uchida T.

**Cardiovasc Interv Ther.** 2014 Jan;29(1):1-3.

33. [Response to letter regarding article, "fractional flow reserve assessment of left main stenosis](#)

[in the presence of downstream coronary stenoses"](#). Yong AS, Daniels D, Kim HS, **Ikeno F**,

Lyons J, Fearon WF, Pijls NH, De Bruyne B. **Circ Cardiovasc Interv.** 2013 Aug;6(4):e57.

34. [Fractional flow reserve assessment of left main stenosis in the presence of downstream](#)

[coronary stenoses.](#) Yong AS, Daniels D, De Bruyne B, Kim HS, **Ikeno F**, Lyons J, Pijls NH,

Fearon WF. **Circ Cardiovasc Interv.** 2013 Apr;6(2):161-5.

35. [Global cardiovascular device innovation: Japan-USA synergies: Harmonization by Doing](#)

[\(HBD\) program, a consortium of regulatory agencies, medical device industry, and academic](#)

[institutions.](#) Uchida T, **Ikeno F**, Ikeda K, Suzuki Y, Todaka K, Yokoi H, Thompson G,

Krucoff M, Saito S; Harmonization by Doing Program Working Group.

CircJ. 2013;77(7):1714-8.

36. [Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes \(BARI 2D\) trial.](#) Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, Krone RJ, Sako EY, Rogers WJ, Garber AJ, King SB 3rd, Davidson CJ, **Ikeno F**, Frye RL; BARI 2D Study Group. *Circulation*. 2012 Oct 23;126(17):2115-24.
37. [Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activation.](#) Gu M, Nguyen PK, Lee AS, Xu D, Hu S, Plews JR, Han L, Huber BC, Lee WH, Gong Y, de Almeida PE, Lyons J, **Ikeno F**, Pacharinsak C, Connolly AJ, Gambhir SS, Robbins RC, Longaker MT, Wu JC. *Circ Res*. 2012 Sep 14;111(7):882-93.
38. [Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization](#)

[Investigation 2 Diabetes \(BARI 2D\)](#). Schwartz L, Bertolet M, Feit F, Fuentes F, Sako EY, Toosi MS, Davidson CJ, **Ikeno F**, King SB 3rd.

*Circ Cardiovasc Interv*. 2012 Apr;5(2):166-73.

39. [Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation](#). Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B, Bruining N, Cho JM, Chowdhary S, Costa MA, de Silva R, Dijkstra J, Di Mario C, Dudek D, Falk E, Feldman MD, Fitzgerald P, Garcia-Garcia HM, Gonzalo N, Granada JF, Guagliumi G, Holm NR, Honda Y, **Ikeno F**, Kawasaki M, Kochman J, Koltowski L, Kubo T, Kume T, Kyono H, Lam CC, Lamouche G, Lee DP, Leon MB, Maehara A, Manfrini O, Mintz GS, Mizuno K, Morel MA, Nadkarni S, Okura H, Otake H, Pietrasik A, Prati F, Räber L, Radu MD, Rieber J, Riga M, Rollins A, Rosenberg M, Sirbu V, Serruys PW, Shimada K, Shinke T, Shite J, Siegel E, Sonoda S, Suter M, Takarada S, Tanaka A, Terashima M, Thim T,

Uemura S, Ughi GJ, van Beusekom HM, van der Steen AF, van Es GA, van Soest G, Virmani R, Waxman S, Weissman NJ, Weisz G; International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT).

*J Am Coll Cardiol.* 2012 Mar 20;59(12):1058-72.

40. [Fundamental wire technique and current standard strategy of percutaneous intervention for](#)

[chronic total occlusion with histopathological insights.](#) Sumitsuji S, Inoue K, Ochiai M,

Tsuchikane E, **Ikeno F.** *JACC Cardiovasc Interv.* 2011 Sep;4(9):941-51.

41. [Dual manganese-enhanced and delayed gadolinium-enhanced MRI detects myocardial](#)

[border zone injury in a pig ischemia-reperfusion model.](#) Dash R, Chung J, **Ikeno F,**

Hahn-Windgassen A, Matsuura Y, Bennett MV, Lyons JK, Teramoto T, Robbins RC,

McConnell MV, Yeung AC, Brinton TJ, Harnish PP, Yang PC.

*Circ Cardiovasc Imaging.* 2011 Sep;4(5):574-82.

42. [Preclinical derivation and imaging of autologously transplanted canine induced pluripotent](#)

[stem cells.](#) Lee AS, Xu D, Plews JR, Nguyen PK, Nag D, Lyons JK, Han L, Hu S, Lan F, Liu J, Huang M, Narsinh KH, Long CT, de Almeida PE, Levi B, Kooreman N, Bangs C, Pacharinsak C, **Ikeno F**, Yeung AC, Gambhir SS, Robbins RC, Longaker MT, Wu JC. *J Biol Chem.* 2011 Sep 16;286(37):32697-704.

43. [Comparison of drug-eluting versus bare metal stents in cardiac allograft vasculopathy.](#)

Tremmel JA, Ng MK, **Ikeno F**, Hunt SA, Lee DP, Yeung AC, Fearon WF. *Am J Cardiol.* 2011 Sep 1;108(5):665-8.

44. [The prevalence and predictors of an abnormal ankle-brachial index in the Bypass](#)

[Angioplasty Revascularization Investigation 2 Diabetes \(BARI 2D\) trial.](#) Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW; Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. *Diabetes Care.* 2011 Feb;34(2):464-7.

45. [The representative porcine model for human cardiovascular disease.](#) Suzuki Y, Yeung AC,

Ikeno F.

J Biomed Biotechnol. 2011;2011:195483.

46. [BMP promotes motility and represses growth of smooth muscle cells by activation of tandem](#)

[Wnt pathways.](#) Perez VA, Ali Z, Alastalo TP, Ikeno F, Sawada H, Lai YJ, Kleisli T,

Spiekerkoetter E, Qu X, Rubinos LH, Ashley E, Amieva M, Dedhar S, Rabinovitch M.

J Cell Biol. 2011 Jan 10;192(1):171-88.

47. [Evaluation of the peri-strut low intensity area following sirolimus- and paclitaxel-eluting](#)

[stents implantation: insights from an optical coherence tomography study in humans.](#) Otake

H, Shite J, Ikeno F, Shinke T, Teramoto T, Miyoshi N, Ako J, Honda Y, Fitzgerald PJ,

Hirata K.

Int J Cardiol. 2012 May 17;157(1):38-42.

48. [Sustained inhibition of epsilon protein kinase C inhibits vascular restenosis after balloon](#)

[injury and stenting.](#) Deuse T, Koyanagi T, Erben RG, Hua X, Velden J, Ikeno F,

Reichenspurner H, Robbins RC, Mochly-Rosen D, Schrepfer S. *Circulation*. 2010 Sep 14;122(11 Suppl):S170-8.

49. [Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME \(Fractional Flow Reserve Versus Angiography for Multivessel Evaluation\) study.](#) Pijls NH, Fearon WF, Tonino PA, Siebert U, **Ikeno F**, Bornschein B, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B; FAME Study Investigators. *J Am Coll Cardiol*. 2010 Jul 13;56(3):177-84.
50. [Intriguing peri-strut low-intensity area detected by optical coherence tomography after coronary stent deployment.](#) Teramoto T, **Ikeno F**, Otake H, Lyons JK, van Beusekom HM, Fearon WF, Yeung AC. *Circ J*. 2010 Jun;74(6):1257-9.
51. [Imaging in-stent restenosis: an inexpensive, reliable, and rapid preclinical model.](#) Deuse T,



**Ikeno F**, Robbins RC, Schrepfer S.

J Vis Exp. 2009 Sep 14;(31).

52. [A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS \(Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study\).](#) Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K, Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M, Fitzgerald PJ, **Ikeno F**, Honda Y, Yoshiyama M, Yoshikawa J; POPPS Investigators.
- a. JACC Cardiovasc Interv. 2009 Jun;2(6):524-31.

53. [A randomized trial of therapies for type 2 diabetes and coronary artery disease.](#) BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. N Engl J Med. 2009 Jun 11;360(24):2503-15.

54. [The pre-clinical animal model in the translational research of interventional cardiology.](#)

Suzuki Y, Yeung AC, **Ikeno F**. JACC Cardiovasc Interv. 2009 May;2(5):373-83.

55. [Tissue sirolimus levels of distal vessel, stented myocardium, and distal myocardium.](#) Kaneda

H, Yeung A, **Ikeno F**. JACC Cardiovasc Interv. 2008 Oct;1(5):595; author reply 595.

56. [In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation.](#) Suzuki Y, **Ikeno F**,

Koizumi T, Tio F, Yeung AC, Yock PG, Fitzgerald PJ, Fearon WF. JACC Cardiovasc Interv. 2008 Apr;1(2):168-73.

57. [Intraoperative fluorescence imaging system for on-site assessment of off-pump coronary artery bypass graft.](#) Waseda K, Ako J, Hasegawa T, Shimada Y, **Ikeno F**, Ishikawa T,

Demura Y, Hatada K, Yock PG, Honda Y, Fitzgerald PJ, Takahashi M. JACC Cardiovasc Imaging. 2009 May;2(5):604-12.

58. [Imaging gene expression in human mesenchymal stem cells: from small to large animals.](#)

Willmann JK, Paulmurugan R, Rodriguez-Porcel M, Stein W, Brinton TJ, Connolly AJ,

Nielsen CH, Lutz AM, Lyons J, **Ikeno F**, Suzuki Y, Rosenberg J, Chen IY, Wu JC, Yeung

AC, Yock P, Robbins RC, Gambhir SS. *Radiology*. 2009 Jul;252(1):117-27.

59. [Development of animal model for calcified chronic total occlusion.](#) Suzuki Y, Oyane A,

**Ikeno F**, Lyons JK, Yeung AC. *Catheter Cardiovasc Interv*. 2009 Sep 1;74(3):468-75.

60. [Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at](#)

[baseline in the BARI 2D cohort.](#) Pop-Busui R, Lu J, Lopes N, Jones TL; BARI 2D

Investigators. *J Peripher Nerv Syst*. 2009 Mar;14(1):1-13.

61. [Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.](#)

Tonino PA, De Bruyne B, Pijls NH, Siebert U, **Ikeno F**, van' t Veer M, Klauss V,

Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF;

FAME Study Investigators. *N Engl J Med*. 2009 Jan 15;360(3):213-24.

62. [The importance of pre-clinical animal testing in interventional cardiology.](#) Suzuki Y, Yeung AC, **Ikeno F.** *Arq Bras Cardiol.* 2008 Nov;91(5):348-60. Review. English, Portuguese.
63. [Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes \(BARI 2D\) trial.](#) Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. *Am Heart J.* 2008 Sep;156(3):528-536, 536.e1-5.
64. [The porcine restenosis model using thermal balloon injury: comparison with the model by coronary stenting.](#) Suzuki Y, Lyons JK, Yeung AC, **Ikeno F.** *J Invasive Cardiol.* 2008 Mar;20(3):142-6.
65. [Introducing the first polymer-free leflunomide eluting stent.](#) Deuse T, Erben RG, **Ikeno F,** Behnisch B, Boeger R, Connolly AJ, Reichenspurner H, Bergow C, Pelletier MP, Robbins RC, Schrepfer S. *Atherosclerosis.* 2008 Sep;200(1):126-34.
66. [Preserved coronary endothelial function by inhibition of delta protein kinase C in a porcine](#)

- [acute myocardial infarction model.](#) Kaneda H, **Ikeno F**, Inagaki K, Mochly-Rosen D. *Int J Cardiol.* 2009 Apr 3;133(2):256-9.
67. [Reporter gene imaging following percutaneous delivery in swine moving toward clinical applications.](#) Rodriguez-Porcel M, Brinton TJ, Chen IY, Gheysens O, Lyons J, **Ikeno F**, Willmann JK, Wu L, Wu JC, Yeung AC, Yock P, Gambhir SS. *J Am Coll Cardiol.* 2008 Feb 5;51(5):595-7.
68. [In vivo porcine model of reperfused myocardial infarction: in situ double staining to measure precise infarct area/area at risk.](#) Suzuki Y, Lyons JK, Yeung AC, **Ikeno F**. *Catheter Cardiovasc Interv.* 2008 Jan 1;71(1):100-7.
69. [Novel stent system for accurate placement in aorto-ostial renal artery disease: preclinical study in porcine renal artery model.](#) Suzuki Y, **Ikeno F**, Lyons JK, Koizumi T, Yeung AC. *Cardiovasc Revasc Med.* 2007 Apr-Jun;8(2):99-102.
70. [Comparison of nonuniform strut distribution between two drug-eluting stent platforms.](#)

Hasegawa T, Ako J, **Ikeno F**, Waseda K, Suzuki Y, Honda Y, Fitzgerald PJ. *J Invasive Cardiol.* 2007 Jun;19(6):244-6.

71. [Mechanism of luminal gain with plaque excision in atherosclerotic coronary and peripheral arteries: assessment by histology and intravascular ultrasound.](#) **Ikeno F**, Braden GA, Kaneda H, Hongo Y, Hinohara T, Yeung AC, Simpson JB, Kandzari DE. *J Interv Cardiol.* 2007 Apr;20(2):107-13.
72. [Novel stent and delivery systems for the treatment of bifurcation lesions: porcine coronary artery model.](#) **Ikeno F**, Buchbinder M, Yeung AC. *Cardiovasc Revasc Med.* 2007 Jan-Mar;8(1):38-42.
73. [Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage.](#) **Ikeno F**, Inagaki K, Rezaee M, Mochly-Rosen D. *Cardiovasc Res.* 2007 Mar 1;73(4):699-709.
74. [Comparison of nonuniform rotational distortion between mechanical IVUS and OCT using](#)

- [a phantom model.](#) Kawase Y, Suzuki Y, **Ikeno F**, Yoneyama R, Hoshino K, Ly HQ, Lau GT, Hayase M, Yeung AC, Hajjar RJ, Jang IK. *Ultrasound Med Biol.* 2007 Jan;33(1):67-73.
75. [Endovascular intervention for infrainguinal artery disease requires additional evidence regarding selection of devices.](#) **Ikeno F**. *J Vasc Interv Radiol.* 2006 Sep;17(9):1545.
76. [Arteriotomy closure device application following percutaneous coronary intervention may prevent bleeding complications in patients with acute myocardial infarction.](#) **Ikeno F**, Sadoughi MA, Lyons JK, Raissi Shabari F, Pourdehmobed K, Hashemi V, Emami S, Kaneda H, Yeung AC, Rezaee M. *Int J Cardiol.* 2007 Apr 12;117(1):131-2.
77. [Drug-eluting stent strut distribution: a comparison between Cypher and Taxus by optical coherence tomography.](#) Suzuki Y, **Ikeno F**, Yeung AC. *J Invasive Cardiol.* 2006 Mar;18(3):111-4.
78. [Long-term histopathologic and IVUS evaluations of a novel coiled sheet stent in porcine](#)

[carotid arteries.](#) Kaneda H, **Ikeno F**, Lyons J, Rezaee M, Yeung AC, Fitzgerald PJ.

Cardiovasc Intervent Radiol. 2006 May-Jun;29(3):413-9.

79. [Acute and long-term outcomes of the novel side access \(SLK-View\) stent for bifurcation](#)

[coronary lesions: a multicenter nonrandomized feasibility study.](#) **Ikeno F**, Kim YH, Luna J,

Condado JA, Colombo A, Grube E, Fitzgerald PJ, Park SJ, Yeung AC.

Catheter Cardiovasc Interv. 2006 Feb;67(2):198-206.

80. [Augmentation of tissue perfusion by a novel compression device increases neurologically](#)

[intact survival in a porcine model of prolonged cardiac arrest.](#) **Ikeno F**, Kaneda H, Hongo Y,

Sakanoue Y, Nolasco C, Emami S, Lyons J, Rezaee M. **Resuscitation.** 2006

Jan;68(1):109-18.

81. [The conversion in application of percutaneous coronary intervention following the](#)

[introduction of drug eluting stents.](#) **Ikeno F**, Raissi Shabari F, Sadoughi A, Lyons JK,

Pourdehmobed K, Hashemi V, Emami S, Kaneda H, Yeung AC, Rezaee M. **Int J Cardiol.**



2006 Nov 10;113(2):279-80.

82. [Effect of lumen narrowing within coronary stents on proximal and distal vessel segments following bare metal stent implantation.](#) Kaneda H, Ako J, Kataoka T, Miyazawa A, Terashima M, **Ikeno F**, Sonoda S, Shimada Y, Morino Y, Honda Y, Yock PG, Fitzgerald PJ. *Am J Cardiol.* 2005 Aug 1;96(3):376-8.
83. [Cardioprotection by epsilon-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase C-activating peptide.](#) Inagaki K, Begley R, **Ikeno F**, Mochly-Rosen D. *Circulation.* 2005 Jan 4;111(1):44-50.
84. [Novel percutaneous adventitial drug delivery system for regional vascular treatment.](#) **Ikeno F**, Lyons J, Kaneda H, Baluom M, Benet LZ, Rezaee M. *Catheter Cardiovasc Interv.* 2004 Oct;63(2):222-30.
85. [Initial experience with the novel 6 Fr-compatible system for debulking de novo coronary arterial lesions.](#) **Ikeno F**, Abizaid A, Suzuki T, Rezaee M, Patterson GR, Yeung AC,

- Virmani R, Sousa JE, Carter AJ. **Catheter Cardiovasc Interv.** 2004 Jul;62(3):308-17.
86. [Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.](#) Grube E, Sonoda S, **Ikeno F**, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ. **Circulation.** 2004 May 11;109(18):2168-71.
87. [Evaluation of high-pressure retrograde coronary venous delivery of FGF-2 protein.](#) Fearon WF, **Ikeno F**, Bailey LR, Hiatt BL, Herity NA, Carter AJ, Fitzgerald PJ, Rezaee M, Yeung AC, Yock PG. **Catheter Cardiovasc Interv.** 2004 Mar;61(3):422-8.
88. [Early experience with a novel plaque excision system for the treatment of complex coronary lesions.](#) **Ikeno F**, Hinohara T, Robertson GC, Rezaee M, Yock PG, Reimers B, Colombo A, Grube E, Simpson JB. **Catheter Cardiovasc Interv.** 2004 Jan;61(1):35-43.
89. [Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo.](#) Inagaki K, Chen L, **Ikeno F**, Lee FH, Imahashi K, Bouley DM, Rezaee M, Yock PG, Murphy E, Mochly-Rosen D. **Circulation.** 2003 Nov 11;108(19):2304-7.

90. [Noninvasive transcutaneous ultrasound augments thrombolysis in the left circumflex coronary artery--an in vivo canine study.](#) Jeon DS, Luo H, Fishbein MC, Miyamoto T, Horzewski M, Iwami T, Mirocha JM, **Ikeno F**, Honda Y, Siegel RJ. *Thromb Res.* 2003 May 1;110(2-3):149-58.
91. [Coronary vasodilation by noninvasive transcutaneous ultrasound: an in vivo canine study.](#) Miyamoto T, Neuman Y, Luo H, Jeon DS, Kobal S, **Ikeno F**, Horzewski M, Honda Y, Mirocha JM, Iwami T, Echt D, Fishbein MC, Siegel RJ. *J Am Coll Cardiol.* 2003 May 7;41(9):1623-7.
92. [Efficacy and feasibility of helixcision for debulking neointimal hyperplasia for in-stent restenosis.](#) Nakamura M, Fitzgerald PJ, **Ikeno F**, Honda Y, Sousa JE, Abizaid A, de Brito FS Jr, Tofte A, Grube E, Patterson GR, Yock PG, Yeung AC, Carter AJ. *Catheter Cardiovasc Interv.* 2002 Dec;57(4):460-6.
93. [Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail.](#) Hiatt BL,

Ikeno E, Yeung AC, Carter AJ. *Catheter Cardiovasc Interv.* 2002 Mar;55(3):409-17.

94. [Will there always be an edge to radiation for the prevention of restenosis?](#)

Ikeno E, Carter AJ. *Catheter Cardiovasc Interv.* 2001 Sep;54(1):49-50.

### **Invited Lecture:**

1. Japan FDA Town Hall meeting. Course Director

Cardiovascular Research Technology (CRT) 2019 in Washington DC, March 4, 2019

<http://www.crtmeeting.org/main/meeting-at-a-glance>

2. US-Japan Harmonization by Doing (HBD): Medical Device Regulatory Convergency

Project between Japan and US. Speaker Transcatheter Cardiovascular Therapeutics (TCT)

2019 in San Diego, September 22, 2019

3. LED Forum in Tokushima: Speaker, Tokushima, Japan Feb. 12, 2018

4. Medical Japan Osaka: Speaker, Osaka, Japan Feb 22, 2018
  
5. Japan Endovascular therapeutics (JET) 2018: Speaker, Tokyo, Japan, Feb 23, 2018
  
6. Japan Clinical Trial Society annual conference 2018: Speaker, Sendai, Japan, Feb 24, 2018
  
7. Japan FDA Town Hall meeting. Course Director  
  
Cardiovascular Research Technology (CRT) 2018 in Washington DC, March 6, 2018
  
8. Osaka Cross Innovation Conference 2018: Speaker, Osaka, Japan, March 12, 2018
  
9. China Interventional Therapeutics (CIT) 2018: Speaker, Beijing, China, March 23, 2018
  
10. Japan Circulation Society (JCS) 2018 annual Conference: Osaka, Japan, March 25, 2018

11. Japan Radiology Technology Society Annual Conference 2018: Speaker, Yokohama, Japan,

April 13, 2018

12. US San Diego Japanese Researchers' Association: Speaker, San Diego, CA, April 14, 2018

13. Tohoku University Biomedical Engineering the 10<sup>th</sup> anniversary: Speaker, Sendai, Japan,

April 21, 2018

14. Slender Club Japan 2018 Annual Conference: Town Hall Meeting, Tokyo, April 29

15. TCTAP (Asian Pacific) 2018: Seoul, South Korea, April 30, 2018

16. Taiwan SPARK conference: Speaker, Taipei, Taiwan, May 6, 2018

17. IT Healthcare Conference 2018: Discussant, Kawasaki, Japan, June 2, 2018
18. The anniversary of foundation of Hamamatsu Medical University: Speaker, June 7, 2018
19. The biomedical engineering Society annual Meeting 2018: Speaker, Sapporo Japan, June 19, 2018
20. Toyohashi Live Demonstration 2018: Director, Biodesign Course, Toyohashi, Japan, June, 21, 22, 2018
21. NEXT National Cancer Center EAST conference 2018: Speaker, Tokyo, Japan, June 26, 2018
22. Regulatory Science Conference 2018: Speaker, Tokyo, Japan, June 29, 2018
23. Japan biodesign 1 day seminar: Lecturer, Tokyo, Japan, July 6, 2018

24. SPARK Summer course in Berlin: Mentor, Berlin, Germany, July 15-26

25. Japanese Society Cardiovascular Interventional Therapeutics (CVIT) 2018 annual  
conference: Moderator of HBD session, Kobe, Japan, Aug 4<sup>th</sup>, 2018

26. University Network for Innovation and Technology Transfer (UNITT) 2018: Speaker,  
Tokyo, Japan, Sep 2, 2018

27. Well Aging Summit 2018: Moderator, Tokyo, Oct 9<sup>th</sup>, 2018

28. The society of Japanese Neurosurgery annual conference 2018: Speaker, Sendai, Japan, Oct  
11<sup>th</sup>, 2018

29. Photonic Fair 2018: Speaker, Hamamatsu City, Japan, Nov 2<sup>nd</sup>, 2018



30. US-Japan MedTech Frontier Annual Conference 2018 in Shizuoka, Japan, Nov 7<sup>th</sup>, 2018

31. Japanese Society of Neuroendovascular Therapeutics Annual Conference 2018: Speaker,  
Sendai, Japan, Nov 22, 2018

32. ARIA 2018: Speaker, Fukuoka, Japan, Nov 23, 2018

33. Health 2.0 Asia 2018: Moderator, Tokyo, Dec 4<sup>th</sup>, 2018